Condition: Relapsed or Refractory Multiple Myeloma · Sponsor: Zhejiang ACEA Pharmaceutical Co. Ltd.
This is a phase Ib/IIa, open-label, dose-escalation, and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.
This description comes directly from the study's public registry record.
chao wang, master · 15838131673 · chao.wang@aceapharma.com
meiping kong, bachelor · 13735478976 · meiping.kong@aceapharma.com
Always discuss trial participation with your own doctor first.
| Beijing Chao-Yang Hospital，Capital Medicine University | Beijing, Beijing Municipality, China | Recruiting |
| Peking university Third hospital | Beijing, Beijing Municipality, China | Recruiting |
| The first affiliated hospital ,Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05565807